[First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept].
Drugs antagonizing tumor necrosis factor (TNF) alpha have been increasingly and successfully used in the treatment of psoriasis vulgaris and psoriatic arthritis. We report a patient with TNF receptor 1-associated periodic syndrome (TRAPS) who received TNF-alpha antagonist etanercept. A month later, the patient developed for the first time generalized psoriasis vulgaris. This paradoxical phenomenon has been reported sporadically in patients receiving TNF-alpha antagonists for other inflammatory diseases. The cause of psoriasis induced by TNF-alpha antagonists is still obscure.
Boms
S
S
Universitäts-Hautklinik, Ruprecht-Karls Universität Heidelberg, Vossstrasse 2, 69115 Heidelberg. Stefanie.Boms@med.uni-heidelberg.de
Sehr
T
T
Jappe
U
U
Enk
A
A
D000328:Adult; D001706:Biopsy; D002881:Chromosomes, Human, Pair 12; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D000068800:Etanercept; D010505:Familial Mediterranean Fever / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D011565:Psoriasis / Q000139:chemically induced* / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000037:antagonists & inhibitors*; D012867:Skin / Q000473:pathology
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D000068800:Etanercept